Expertise in
5
conditions

Giampaolo Bianchini

Milan, IT 
Expertise in
5
conditions
Milan, IT 

Overview

Giampaolo Bianchini practices practicing medicine in Milan, Italy.

Bianchini is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, HER2 Negative Breast Cancer, and Mastectomy.

They are actively involved in clinical research, co-authoring 155 peer reviewed articles and participating in 2 clinical trials.

Locations

Milan, Italy
Other Locations
Ferrara, Italy
Cremona, Italy
Via Panciatichi 64, Florence, 50127, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Atezolizumab, Pertuzumab and Trastuzumab With Chemotherapy as Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)
Atezolizumab, Pertuzumab and Trastuzumab With Chemotherapy as Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2024
Intervention Type: Drug, Procedure
Study Drugs: Trastuzumab, Pertuzumab, Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide, Atezolizumab
Study Phase: Phase 3
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
View 1 Less Clinical Trial

155 Total Publications

TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.
Journal: Future oncology (London, England)
Published: July 31, 2026

Frequently Asked Questions about Giampaolo Bianchini

Is Giampaolo Bianchini a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Giampaolo Bianchini is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Giampaolo Bianchini participate in research or clinical trials?

Yes. Giampaolo Bianchini has published 155 articles and abstracts on conditions like Breast Cancer. You can view a list of Giampaolo Bianchini's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bianchini's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile